This content is only available within our institutional offering.
19 Jul 2023
Going through difficult times
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Going through difficult times
Probiodrug (PBD:AMS), 0 | Probiotec Limited (PBP:ASX), 0 | Probiotix Health Plc (PBX:PLU), 0 | Probi AB (PROB:OME), 0 | ProBility Media Corporation (PBYA:OTC), 0 | Probi AB (0GZB:LON), 0
- Published:
19 Jul 2023 -
Author:
Gonzalo Artiach | ABGSC Food & Beverage Research -
Pages:
11
Weak orders in Americas and EMEA plus high COGS/SG&A costs hurt profitability. Share trading at NTM EV/EBITA of 28x-12x for '23-'25.